Physician profile
Brad A Liston
NPI 1487817375
$8,325.18
in general payments reported to CMS, 2019-2025
30 companies · $896 in 2025
The $896 reported for 2025 was more than what 82% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $1,053 · 2021: $1,444 · 2022: $1,133 · 2023: $1,367 · 2024: $1,147 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,404 · Education: $5.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,404.48 |
| Education | $5.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,096.68 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,380.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,063.20 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.39 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $420.55 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $371.02 | 2019-2022 | |
| Pfizer INC. | $237.42 | 2019-2021 | |
| Exact Sciences Corporation | $189.55 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $187.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $155.02 | 2019-2024 | Repatha, Otezla |
| Mylan Specialty L.P. | $99.53 | 2019-2022 | |
| Amarin Pharma, INC. | $69.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $41.06 | 2021-2023 | |
| Viatris Specialty LLC | $40.29 | 2025 | Yupelri |
| Abbvie INC. | $39.63 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.88 | 2022 | |
| Eisai INC. | $36.18 | 2021 | |
| Xeris Pharmaceuticals, INC. | $33.72 | 2022-2023 | Gvoke Hypopen |
| Dexcom, INC. | $30.21 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $27.74 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.14 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.84 | 2022 | |
| Ucb, INC. | $18.74 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.70 | 2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $16.22 | 2024 | Voquezna |
| Genentech USA, INC. | $15.08 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.77 | 2024 | Zoryve |
| Antares Pharma, INC. | $14.00 | 2023 | Xyosted, Tlando, Nocdurna |
| Allergan, INC. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Liston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.